Wednesday, April 25, 2018

FDA’s Strategic Policy Roadmap for 2018

For Kapstone Medical


FDA Commissioner aims to streamline review and beef up technical support
FDA Commissioner Scott Gottlieb, MD laid out an 18-page "roadmap" for achieving the FDA’s 2018 goals and objectives. The broad sweep of initiatives addresses four main objectives: reducing opiod and other addictions, leveraging innovation and competition, empowering consumers and strengthening FDA’s scientific workforce.

Tuesday, April 24, 2018

New Hope for Migraine Sufferers

For Healthcare Associates of Texas

Anyone who suffers from migraines knows they aren’t just bad headaches. Migraines can have symptoms that include severe throbbing pain on one side of the head, flashes of light, blind spots and even tingling on one side of the face. These symptoms can last for hours, and they’re the results of a little-understood neurological disease. (published site)

Tuesday, April 17, 2018

Fast 3D Printing of Living Cells While Maintaining Viability

POSTED FOR KAPSTONE MEDICAL
living cells
A major challenge to 3D printing living tissues is that many 3D printing techniques are based on using heat or ultraviolet light, which can damage or kill living cells.

To address this challenge, researchers at the University of Twente (UT) in Enschede, Netherlands are taking a page from biochip technology that adapted microfluidics for a variety of biocompatible applications.

Tuesday, April 3, 2018

Is mpMRI the Key to Making Smarter Use of Ablative Technologies?

For Sonacare Medical on Apr 3, 2018 
Focal therapies for cancer have been around for more than two decades and have been accepted treatment options for breast and renal cancers. Gaining acceptance for prostate cancer, however, has been a long-winding road. (published site)

Monday, April 2, 2018

FDA Announces Updates to “Refuse to Accept Policy”

For Kapstone Medical

7 questions to ask before submitting 501(k)

The FDA recently issued updates to its guidance for its “Refuse to Accept Policy for 510(k)s” for Center for Biologics Evaluation and Research-regulated (CBER) devices and for “Acceptance and Filing Reviews for Premarket Approval Applications (PMAs).” (published site)